CryoLife this week said it signed a distribution agreement with Misonix where Misonix will have exclusive commercialization rights of NeoPatch.
The NeoPatch, made by CryoLife, is a dehydrated and terminally sterilized chorioamniotic allograft that is made from human placental membrane. It is designed to treat a wide range of indications outside of cardiac and vascular surgery.
“Misonix is the perfect partner to commercialize NeoPatch due to its knowledge and expertise in the wound care business,” CryoLife CEO Pat Mackin said in a news release. “We expect to commence supplying NeoPatch to Misonix on a pilot basis beginning in the first quarter of 2020, with a full commercial launch in the second quarter. The clinical data for NeoPatch in wound closure, coupled with our securing high-cost reimbursement, will allow for a successful launch of NeoPatch.”
NeoPatch can also be used in advanced wound care applications as a skin substitute on chronic wounds, as well as in orthopedic applications as an anti-adhesion barrier and surgical applications such as nerve and tendon repair.
“We are excited to add an additional product offering in the wound biologics market and pleased to enter into this agreement with CryoLife, a leading medical device and implantable tissue provider,” Misonix CEO Stavros Vizitgianakis said. “NeoPatch is very complementary to our existing wound franchise, including SonicOne and TheraSkin, and will serve as a new source of growth for the company. This agreement further demonstrates the strength and potential of Misonix’s expanding wound offering and sales and distribution capabilities following the acquisition of Solsys Medical earlier this year. Looking ahead, we intend to further grow our wound care portfolio via both in-house initiative as well as licensing and acquisition arrangements that further leverage our channel to market, which provide healthcare practitioners and patients with improved outcomes.”